The genotypes of SH2B3, MTHFD1L, GGCX, and ITGB3 polymorphisms, plus clinical data for the participants, were evaluated to investigate their effects on the risk of cardiovascular disease and warfarin sensitivity and responsiveness during the initial phase treatment. This evidence concerns the gene ITGB3 and cardiovascular disorder.